West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+56.7%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

397.86 5.38 +1.37%
Market cap
$27.3B
P/E
43.8×
Fwd P/E
48.1×
Dividend yield
0.22%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100

West Pharmaceutical Services, Inc. 8-K filed Apr 25, 2024

Period ended Apr 25, 2024 · Filed · accepted 7:42 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release